Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Meta Expands AI Training With Employee Activity Tracking Tools 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
 and Lead Plaintiff Deadline: July 7, 2017 - EconoTimes)
NEW YORK, May 17, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. (“Puma” or the “Company”) (NASDAQ:PBYI) and certain of its officers, on behalf of shareholders who purchased Puma securities between February 29, 2016 and May 4, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pbyi.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Puma did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (2) consequently, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (3) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
On May 4, 2017, post-market, Puma revealed that Dr. Robert Charnas, the Company’s Senior Vice President, Regulatory Affairs, would be stepping down for “health reasons.” Dr. Charnas’s resignation was effective as of May 15, 2017, nine days before the U.S. Food and Drug Administration’s scheduled review of Puma’s breast cancer drug neratinib on May 24. Following this news, Puma stock dropped.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/pbyi or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Puma you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
